![Continentality determines warming or cooling impact of heavy rainfall events on permafrost | Nature Communications Continentality determines warming or cooling impact of heavy rainfall events on permafrost | Nature Communications](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41467-023-39325-4/MediaObjects/41467_2023_39325_Fig1_HTML.png)
Continentality determines warming or cooling impact of heavy rainfall events on permafrost | Nature Communications
![It was the missing piece”: adolescent experiences of predictive genetic testing for adult-onset conditions - Genetics in Medicine It was the missing piece”: adolescent experiences of predictive genetic testing for adult-onset conditions - Genetics in Medicine](https://www.gimjournal.org/cms/asset/024657fb-233e-42eb-a01c-5270bf6787ca/fx1.jpg)
It was the missing piece”: adolescent experiences of predictive genetic testing for adult-onset conditions - Genetics in Medicine
![Frontiers | The Role of Immune Cells in Post-Stroke Angiogenesis and Neuronal Remodeling: The Known and the Unknown Frontiers | The Role of Immune Cells in Post-Stroke Angiogenesis and Neuronal Remodeling: The Known and the Unknown](https://www.frontiersin.org/files/Articles/784098/fimmu-12-784098-HTML/image_m/fimmu-12-784098-g001.jpg)
Frontiers | The Role of Immune Cells in Post-Stroke Angiogenesis and Neuronal Remodeling: The Known and the Unknown
![10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial - The Lancet Haematology 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial - The Lancet Haematology](https://www.thelancet.com/cms/asset/0c45a689-4a56-4f12-a71a-4196426b5783/gr1.jpg)
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial - The Lancet Haematology
![Cells | Free Full-Text | Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead Cells | Free Full-Text | Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead](https://pub.mdpi-res.com/cells/cells-10-01450/article_deploy/html/images/cells-10-01450-g001.png?1623744420)